Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- How George Tidmarsh crossed the FDA-industry Rubicon
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval
